These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
486 related articles for article (PubMed ID: 32071302)
1. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Aslan K; Turco V; Blobner J; Sonner JK; Liuzzi AR; Núñez NG; De Feo D; Kickingereder P; Fischer M; Green E; Sadik A; Friedrich M; Sanghvi K; Kilian M; Cichon F; Wolf L; Jähne K; von Landenberg A; Bunse L; Sahm F; Schrimpf D; Meyer J; Alexander A; Brugnara G; Röth R; Pfleiderer K; Niesler B; von Deimling A; Opitz C; Breckwoldt MO; Heiland S; Bendszus M; Wick W; Becher B; Platten M Nat Commun; 2020 Feb; 11(1):931. PubMed ID: 32071302 [TBL] [Abstract][Full Text] [Related]
2. Treg-mediated acquired resistance to immune checkpoint inhibitors. Saleh R; Elkord E Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738 [TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of the Tumor-Infiltrating CD8 Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B Front Immunol; 2021; 12():734956. PubMed ID: 34603316 [TBL] [Abstract][Full Text] [Related]
4. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267 [TBL] [Abstract][Full Text] [Related]
5. Firing Up Cold Tumors. Cheng WC; Ho PC Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357 [TBL] [Abstract][Full Text] [Related]
6. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484 [TBL] [Abstract][Full Text] [Related]
7. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Jiang Y; Zhan H Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776 [TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. de Streel G; Bertrand C; Chalon N; Liénart S; Bricard O; Lecomte S; Devreux J; Gaignage M; De Boeck G; Mariën L; Van De Walle I; van der Woning B; Saunders M; de Haard H; Vermeersch E; Maes W; Deckmyn H; Coulie PG; van Baren N; Lucas S Nat Commun; 2020 Sep; 11(1):4545. PubMed ID: 32917858 [TBL] [Abstract][Full Text] [Related]
9. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928 [TBL] [Abstract][Full Text] [Related]
10. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. Zhang S; Bai X; Shan F Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710 [TBL] [Abstract][Full Text] [Related]
11. T cell checkpoint regulators in the heart. Grabie N; Lichtman AH; Padera R Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928 [TBL] [Abstract][Full Text] [Related]
12. Understanding genetic determinants of resistance to immune checkpoint blockers. Aspeslagh S; Chabanon RM; Champiat S; Postel-Vinay S Semin Cancer Biol; 2020 Oct; 65():123-139. PubMed ID: 31881338 [TBL] [Abstract][Full Text] [Related]
13. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Wainwright DA; Chang AL; Dey M; Balyasnikova IV; Kim CK; Tobias A; Cheng Y; Kim JW; Qiao J; Zhang L; Han Y; Lesniak MS Clin Cancer Res; 2014 Oct; 20(20):5290-301. PubMed ID: 24691018 [TBL] [Abstract][Full Text] [Related]
14. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929 [TBL] [Abstract][Full Text] [Related]
15. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8 Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667 [TBL] [Abstract][Full Text] [Related]
16. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. Hage C; Hoves S; Ashoff M; Schandl V; Hört S; Rieder N; Heichinger C; Berrera M; Ries CH; Kiessling F; Pöschinger T PLoS One; 2019; 14(7):e0219517. PubMed ID: 31291357 [TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma. Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346 [TBL] [Abstract][Full Text] [Related]
18. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098 [TBL] [Abstract][Full Text] [Related]
19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
20. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Hu G; Tu W; Yang L; Peng G; Yang L Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]